Physician profile
James B Rivers
NPI 1033150461
$4,046.06
in general payments reported to CMS, 2019-2025
28 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $189 · 2021: $415 · 2022: $628 · 2023: $919 · 2024: $930 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.30 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $749.57 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $590.79 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $376.79 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $264.79 | 2020-2025 | |
| Abbott Laboratories | $165.18 | 2021-2024 | Freestyle Libre 3, Eterna |
| Amgen INC. | $131.72 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.89 | 2019-2025 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $112.03 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $110.15 | 2021-2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $87.28 | 2021-2023 | |
| Lilly USA, LLC | $80.95 | 2020-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $74.68 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.22 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $46.32 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44.19 | 2020-2023 | |
| Xeris Pharmaceuticals, INC. | $43.48 | 2025 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $35.11 | 2021 | |
| Grifols USA, LLC | $33.32 | 2024 | Xembify |
| Merck Sharp & Dohme LLC | $33.29 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.96 | 2025 | Caplyta |
| Philips North America LLC | $18.76 | 2024 | (Ck7) Extended Holter |
| Janssen Scientific Affairs, LLC | $18.33 | 2024 | Xarelto |
| Nevro Corp. | $16.87 | 2023 | Senza |
| Eisai INC. | $16.07 | 2021 | |
| Endo Pharmaceuticals INC. | $13.88 | 2020 | |
| Endogastric Solutions, INC | $11.18 | 2023 | Esophyx |
| Medtronic Vascular, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rivers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.